Fig. 2From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysisOne-way sensitivity analysis in all randomized patients. A All randomized patients, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatin, PFS Progression-free survival, PD Progressive disease, WTP Willingness to pay, EV Average value, QALY Quality-adjusted life yearBack to article page